← All trials
NCT06364787
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 26, 2024
- Primary completion
- Apr 26, 2026
- Completion date
- Sep 26, 2026
- First posted
- Apr 15, 2024
- Last posted
- Apr 15, 2024
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- People's Liberation Army of ChinaLead sponsor
- Beijing GD Initiative Cell Therapy Technology Co.，Ltd.Collaborator
- Chinese Academy of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.